ImmunityBio (NASDAQ:IBRX - Get Free Report)'s stock had its "buy" rating restated by investment analysts at D. Boral Capital in a note issued to investors on Thursday,Benzinga reports. They presently have a $30.00 price target on the stock.
Several other analysts have also weighed in on the company. EF Hutton Acquisition Co. I upgraded ImmunityBio to a "strong-buy" rating in a report on Wednesday, October 23rd. BTIG Research began coverage on shares of ImmunityBio in a research note on Friday, January 10th. They issued a "buy" rating and a $6.00 target price on the stock.
View Our Latest Research Report on IBRX
ImmunityBio Price Performance
Shares of ImmunityBio stock traded down $0.10 during trading hours on Thursday, reaching $2.94. The company's stock had a trading volume of 11,795,251 shares, compared to its average volume of 6,903,445. ImmunityBio has a one year low of $2.28 and a one year high of $10.53. The firm has a 50 day moving average price of $3.74 and a 200-day moving average price of $4.25. The stock has a market cap of $2.05 billion, a P/E ratio of -3.20 and a beta of 0.86.
Hedge Funds Weigh In On ImmunityBio
A number of large investors have recently bought and sold shares of the business. Captrust Financial Advisors bought a new stake in shares of ImmunityBio during the third quarter worth $41,000. Mutual Advisors LLC bought a new stake in ImmunityBio during the 4th quarter valued at about $41,000. Virtu Financial LLC purchased a new stake in ImmunityBio in the 3rd quarter valued at about $51,000. Algert Global LLC bought a new position in ImmunityBio in the 2nd quarter worth about $86,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of ImmunityBio by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company's stock worth $99,000 after acquiring an additional 4,545 shares during the period. Hedge funds and other institutional investors own 8.58% of the company's stock.
About ImmunityBio
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
See Also
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
